The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment.
Top Investments for 2025: A Focus on the S&P 500
As we move into 2025, the S&P 500 continues to be a cornerstone of investment strategies, offering insights into the U.S. stock market’s health. Following
